Relevance of subcellular localization of extracellular signal-regulated kinase 1/2 (ERK1/2) for cisplatin resistance
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2015 |
|---|---|
| Erschienen: |
2015 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:53 |
|---|---|
| Enthalten in: |
International journal of clinical pharmacology and therapeutics - 53(2015), 12 vom: 28. Dez., Seite 1041-5 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Dilruba, Shahana [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antineoplastic Agents |
|---|
| Anmerkungen: |
Date Completed 11.02.2016 Date Revised 13.11.2015 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.5414/CPXCES14EA03 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM251604381 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM251604381 | ||
| 003 | DE-627 | ||
| 005 | 20231224162348.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2015 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.5414/CPXCES14EA03 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0838.xml |
| 035 | |a (DE-627)NLM251604381 | ||
| 035 | |a (NLM)26249763 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Dilruba, Shahana |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Relevance of subcellular localization of extracellular signal-regulated kinase 1/2 (ERK1/2) for cisplatin resistance |
| 264 | 1 | |c 2015 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 11.02.2016 | ||
| 500 | |a Date Revised 13.11.2015 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a Mitogen-Activated Protein Kinase 1 |2 NLM | |
| 650 | 7 | |a EC 2.7.11.24 |2 NLM | |
| 650 | 7 | |a Mitogen-Activated Protein Kinase 3 |2 NLM | |
| 650 | 7 | |a EC 2.7.11.24 |2 NLM | |
| 650 | 7 | |a Cisplatin |2 NLM | |
| 650 | 7 | |a Q20Q21Q62J |2 NLM | |
| 700 | 1 | |a Michaelis, Martin |e verfasserin |4 aut | |
| 700 | 1 | |a Cinatl, Jindrich |c Jr |e verfasserin |4 aut | |
| 700 | 1 | |a Kalayda, Ganna V |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of clinical pharmacology and therapeutics |d 1997 |g 53(2015), 12 vom: 28. Dez., Seite 1041-5 |w (DE-627)NLM075091739 |x 0946-1965 |7 nnns |
| 773 | 1 | 8 | |g volume:53 |g year:2015 |g number:12 |g day:28 |g month:12 |g pages:1041-5 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.5414/CPXCES14EA03 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 53 |j 2015 |e 12 |b 28 |c 12 |h 1041-5 | ||